Mäki-Nevala S, Ukwattage S, Wirta E-V, Ahtiainen M, Ristimäki A, Seppälä TT , Lepistö A, Mecklin J-P, Peltomäki P.
Immunological and epigenetic changes are interconnected and contribute to tumorigenesis. We determined the immunoprofiles and promoter methylation of inflammation-related genes for colitis-associated colorectal carcinomas (CA-CRC). The results were compared with Lynch syndrome (LS)-associated colorectal tumors, which are characterized by an active immune environment through inherited mismatch repair defects. CA-CRCs (n = 31) were immunohistochemically evaluated for immune cell scores (ICSs) and PDCD1 and CD274 expression. Seven inflammation-associated genes (CD274, NTSR1, PPARG, PTGS2, PYCARD, SOCS1, and SOCS2), the repair gene MGMT, and eight standard marker genes for the CpG Island Methylator Phenotype (CIMP) were investigated for promoter methylation in CA-CRCs, LS tumors (n = 29), and paired normal mucosae by multiplex ligation-dependent probe amplification. All but one CA-CRCs were microsatellite-stable and all LS tumors were microsatellite-unstable. Most CA-CRCs had a high ICS (55%) and a positive CD274 expression in immune cells (52%). NTSR1 revealed frequent tumor-specific hypermethylation in CA-CRC and LS. When compared to LS mucosae, normal mucosae from patients with CA-CRC showed significantly higher methylation of NTSR1 and most CIMP markers. In conclusion, CA-CRCs share a frequent ICShigh/CD274pos expression pattern with LS tumors. Elevated methylation in normal mucosa may indicate field cancerization as a feature of CA-CRC-associated tumorigenesis.
Keywords: Lynch syndrome; ulcerative colitis; colon cancer; immune cell score; DNA methylation; inflammation-associated genes
Biomolecules 2021, 11(10):1440.
Olkinuora A, Peltomäki P, Aaltonen L, Rajamäki K.
Hereditary colorectal cancer syndromes attributable to high penetrance mutations represent 9-26% of young-onset colorectal cancer cases. The clinical significance of many of these mutations is understood well enough to be used in diagnostics and as an aid in patient care. However, despite the advances made in the field, a significant proportion of familial and early-onset cases remains molecularly uncharacterized and extensive work is still needed to fully understand the genetic nature of colorectal cancer susceptibility. With the emergence of next generation sequencing and associated methods, several predisposition loci have been unravelled but validation is incomplete. Individuals with cancer predisposing mutations are currently enrolled in life-long surveillance, but with the development of new treatments, such as cancer vaccinations, this might change in the not so distant future for at least some individuals. For individuals without a known cause for their disease susceptibility, prevention and therapy options are less precise. Herein, we review the progress achieved in the last three decades with a focus on how colorectal cancer predisposition genes were discovered. Furthermore, we discuss the clinical implications of these discoveries and anticipate what to expect in the next decade.
Hum Mol Genet. 2021 Jul 30; ddab208.
Mäki-Nevala S, Ukwattage S, Olkinuora A, Almusa H, Ahtiainen M, Ristimäki A, Seppälä T, Lepistö A, Mecklin JP, Peltomäki P
Ulcerative colitis increases colorectal cancer risk by mechanisms that remain incompletely understood. We approached this question by determining the genetic and epigenetic profiles of colitis-associated colorectal carcinomas (CA-CRC). The findings were compared to Lynch syndrome (LS), a different form of cancer predisposition that shares the importance of immunological factors in tumorigenesis. CA-CRCs (n = 27) were investigated for microsatellite instability, CpG island methylator phenotype and somatic mutations of 999 cancer-relevant genes (“Pan-cancer” panel). A subpanel of “Pan-cancer” design (578 genes) was used for LS colorectal tumors (n = 28). Mutational loads and signatures stratified CA-CRCs into three subgroups: hypermutated microsatellite-unstable (Group 1, n = 1), hypermutated microsatellite-stable (Group 2, n = 9) and nonhypermutated microsatellite-stable (Group 3, n = 17). The Group 1 tumor was the only one with MLH1 promoter hypermethylation and exhibited the mismatch repair deficiency-associated Signatures 21 and 15. Signatures 30 and 32 characterized Group 2, whereas no prominent single signature existed in Group 3. TP53, the most common mutational target in CA-CRC (16/27, 59%), was similarly affected in Groups 2 and 3, but DNA repair genes and Wnt signaling genes were mutated significantly more often in Group 2. In LS tumors, the degree of hypermutability exceeded that of the hypermutated CA-CRC Groups 1 and 2, and somatic mutational profiles and signatures were different. In conclusion, Groups 1 (4%) and 3 (63%) comply with published studies, whereas Group 2 (33%) is novel. The existence of molecularly distinct subgroups within CA-CRC may guide clinical management, such as therapy options.
Keywords: Lynch syndrome; Ulcerative colitis; colorectal cancer; microsatellite instability; somatic mutation.
Int J Cancer. 2021, Jun 15;148(12):2997-3007.
Peltomäki P, Olkinuora A, Nieminen TT
Introduction: Up to one third of colorectal cancers show familial clustering and 5% are hereditary single-gene disorders. Hereditary non-polyposis colorectal cancer comprises DNA mismatch repair-deficient and -proficient subsets, represented by Lynch syndrome (LS) and familial colorectal cancer type X (FCCTX), respectively. Accurate knowledge of molecular etiology and genotype-phenotype correlations are critical for tailored cancer prevention and treatment.
Areas covered: The authors highlight advances in the molecular dissection of hereditary non-polyposis colorectal cancer, based on recent literature retrieved from PubMed. Future possibilities for novel gene discoveries are discussed.
Expert commentary: LS is molecularly well established, but new information is accumulating of the associated clinical and tumor phenotypes. FCCTX remains poorly defined, but several promising candidate genes have been discovered and share some preferential biological pathways. Multi-level characterization of specimens from large patient cohorts representing multiple populations, combined with proper bioinformatic and functional analyses, will be necessary to resolve the outstanding questions.
Keywords: DNA mismatch repair; Hereditary non-polyposis colorectal cancer; constitutional epimutation; familial colorectal cancer type X; genomic instability; germline mutation; lynch syndrome.
Expert Rev Gastroenterol Hepatol. 2020 Aug 5;1-14.
Olkinuora A, Gylling A, Almusa H, Eldfors S, Lepistö A, Mecklin J P, Nieminen T T., & Peltomäki P.
Some 10-50% of Lynch-suspected cases with abnormal immunohistochemical (IHC) staining remain without any identifiable germline mutation of DNA mismatch repair (MMR) genes. MMR proteins form heterodimeric complexes, giving rise to distinct IHC patterns when mutant. Potential reasons for not finding a germline mutation include involvement of an MMR gene not predicted by the IHC pattern, epigenetic mechanism of predisposition, primary mutation in another DNA repair or replication-associated gene, and double somatic MMR gene mutations. We addressed these possibilities by germline and tumor studies in 60 Lynch-suspected cases ascertained through diagnostics (n = 55) or research (n = 5). All cases had abnormal MMR protein staining in tumors but no point mutation or large rearrangement of the suspected MMR genes in the germline. In diagnostic practice, MSH2/MSH6 (MutS Homolog 2/MutS Homolog 6) deficiency prompts MSH2 mutation screening; in our study, 3/11 index individuals (27%) with this IHC pattern revealed pathogenic germline mutations in MSH6. Individuals with isolated absence of MSH6 are routinely screened for MSH6 mutations alone; we found a predisposing mutation in MSH2 in 1/7 such cases (14%). Somatic deletion of the MSH2-MSH6 region, joint loss of MSH6 and MSH3 (MutS Homolog 3) proteins, and hindered MSH2/MSH6 dimerization offered explanations to misleading IHC patterns. Constitutional epimutation hypothesis was pursued in the MSH2 and/or MSH6-deficient cases plus 38 cases with MLH1 (MutL Homolog 1)-deficient tumors; a primary MLH1 epimutation was identified in one case with an MLH1-deficient tumor. We conclude that both MSH2 and MSH6 should be screened in MSH2/6- and MSH6-deficient cases. In MLH1-deficient cases, constitutional epimutations of MLH1 warrant consideration.
Keywords: DNA mismatch repair; Lynch syndrome; colorectal cancer; deep sequencing.
Cancers (Basel) 2020 Jul 9;12(7):E1853.
Mariann Kasela, M.Sc. will defend the doctoral dissertation entitled “Reduced mismatch repair gene expression and functional deficiency as indicators of Lynch syndrome” in the Faculty of Biological and Environmental Sciences, University of Helsinki, on 26 June 2020 at 12:00. The public examination will take place at the following address: Porthania, P673, Yliopistonkatu 3.
Professor Karl Heinimann, University of Basel, Switzerland, will serve as the opponent, and Professor Minna Nyström as the custos.
The dissertation will be published in the series Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Unviersitatis Helsinkiensis.
The dissertation is also available in electronic form through the E-thesis service.
Porkka NK, Olkinuora A, Kuopio T, Ahtiainen M, Eldfors S, Almusa H, Mecklin JP, Peltomäki P.
Inherited DNA mismatch repair (MMR) defects cause predisposition to colorectal, endometrial, ovarian, and other cancers occurring in Lynch syndrome (LS). It is unsettled whether breast carcinoma belongs to the LS tumor spectrum. We approached this question through somatic mutational analysis of breast carcinomas from LS families, using established LS-spectrum tumors for comparison. Somatic mutational profiles of 578 cancer-relevant genes were determined for LS-breast cancer (LS-BC, n = 20), non-carrier breast cancer (NC-BC, n = 10), LS-ovarian cancer (LS-OC, n = 16), and LS-colorectal cancer (LS-CRC, n = 18) from the National LS Registry of Finland. Microsatellite and MMR protein analysis stratified LS-BCs into MMR-deficient (dMMR, n = 11) and MMR-proficient (pMMR, n = 9) subgroups. All NC-BCs were pMMR and all LS-OCs and LS-CRCs dMMR. All but one dMMR LS-BCs were hypermutated (> 10 non-synonymous mutations/Mb; average 174/Mb per tumor) and the frequency of MMR-deficiency-associated signatures 6, 20, and 26 was comparable to that in LS-OC and LS-CRC. LS-BCs that were pMMR resembled NC-BCs with respect to somatic mutational loads (4/9, 44%, hypermutated with average mutation count 33/Mb vs. 3/10, 30%, hypermutated with average 88 mutations/Mb), whereas mutational signatures shared features of dMMR LS-BC, LS-OC, and LS-CRC. Epigenetic regulatory genes were significantly enriched as mutational targets in LS-BC, LS-OC, and LS-CRC. Many top mutant genes of our LS-BCs have previously been identified as drivers of unselected breast carcinomas. In conclusion, somatic mutational signatures suggest that conventional MMR status of tumor tissues is likely to underestimate the significance of the predisposing MMR defects as contributors to breast tumorigenesis in LS.
DNA mismatch repair; Lynch syndrome; MSI; breast carcinoma; somatic mutation
Oncotarget. 2020 Apr 7;11(14):1244-1256.
PubMed ID: 32292574
Public PhD defence on 17th April 2020 at 12:00.
Due to the COVID-19 pandemia, event was arranged only among few individuals and streamed live for the audience via UniTube.
Professor Arto Mannermaa and M.Sc. Noora Porkka
Professor Päivi Peltomäki and M.Sc. Noora Porkka
Author: M.Sc. Noora Porkka
Department of Medical and Clinical Genetics, University of Helsinki
Opponent: Prof. Arto Mannermaa
Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
The 4th EHTG meeting was organized in Barcelona, Spain on 17th-19th October 2019.
Professor Minna Nyström gave a presentation about the DiagMMR®, a novel carrier test to detect inherited MMR deficiency.
Prof., Minna Nyström
PhD Satu Mäki-Nevala and M.Sc Noora Porkka from Professor Päivi Peltomäki’s group presented their latest studies in short oral presentations and as poster presentations.
Satu Mäki-Nevala was awarded a poster award for presenting one of the three best posters in the meeting. Congratulations Satu!
PhD, Satu Mäki-Nevala
PhD, Satu Mäki-Nevala with her award winning poster
M.Sc, Noora Porkka
M.Sc, Noora Porkka
The 7th biennial International Society for Gastrointestinal Hereditary tumors Incorporated (InSIGHT) meeting was organized in Auckland, New Zealand on 20-23rd of March.
M.Sc. Noora Porkka